Highlights Avicanna Inc.

Equities

AVCN

CA05368K1003

Market Closed - Toronto S.E. Other stock markets 20:59:34 16/05/2024 BST			5-day change	1st Jan Change
0.35 ^CAD	-4.11%		+11.11%	0.00%

05-14	Avicanna Up 4.5% as it Books Record Q1 Revenue, First Adjusted EBITDA Positive Quarter in Company History	MT
05-14	Avicanna Books Record Q1 Revenue, First Adjusted Ebitda Positive Quarter in Company History	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Avicanna Up 4.5% as it Books Record Q1 Revenue, First Adjusted EBITDA Positive Quarter in Company History	05-14	MT
Avicanna Books Record Q1 Revenue, First Adjusted Ebitda Positive Quarter in Company History	05-14	MT
Avicanna Brief: Record Q1 revenue of $6.45 million representing a year-over-year increase of 451% compared to Q1 2023	05-14	MT
Avicanna Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-14	CI
Avicanna Announced Results of Study in Patients with Epidermolysis Bullosa	05-13	MT
Avicanna Brief: Announcing Results of Study in Patients with Epidermolysis Bullosa	05-13	MT
Avicanna Raises About $2.1 Million in Non-brokered Private Placement	04-19	MT
Avicanna Inc. Announces Completion of Topical Gel Observational Real-World Evidence Study	04-10	CI
Avicanna's Q4 Loss Narrows, Revenue Grows	04-02	MT
Avicanna Brief: Reporting $16.8 Million in 2023 Revenue, representing an increase of 314% from 2022	04-02	MT
Avicanna Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	04-02	CI
Avicanna Announced Canadian Launch of 10% CBD (THC Free) Proprietary Formulation	03-27	MT
Avicanna Brief: Announcing Canadian Launch of 10% CBD (THC Free) Proprietary Formulation	03-27	MT
Avicanna Inc Announces the Canadian Launch of 10% CBD (THC Free) Proprietary Formulation	03-27	CI
ThreeD Capital Inc. Announces New YouTube Channel	03-25	MT
Avicanna Reports New Research Collaboration With Multi-national European-based Pharmaceutical Firm; Down 5.6%	02-15	MT
Avicanna Reports New Research Collaboration With Multi-national European-based Pharmaceutical Firm	02-15	MT
Avicanna Brief: Announcing New Research Collaboration with a Multi-national European-based Pharmaceutical Company	02-15	MT
Avicanna Inc. Announces New Research Collaboration with a Multi-National European-Based Pharmaceutical Company	02-15	CI
Avicanna Brief: Adds Approval issued by the Health Authority of Colombia INVIMA for Adjuvant treatment for seizures associated with Lennox-Gastaut Syndrome (LGS) and Dravet Syndrome (DS)	02-13	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Avicanna Inc.

Equities

AVCN

CA05368K1003

Highlights

Filters